Aligos Therapeutics, Inc.
ALGS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -23.2% | 210.3% | -50.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 73.2% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -4,154.3% | -1,597.8% | -6,023.5% | -3,162.5% |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -4,256% | -1,643.8% | 13,854.7% | -13,060.4% |
| EPS Diluted | -3.04 | -1.53 | -2.11 | -13.08 |
| % Growth | -98.7% | 27.5% | 83.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |